Search

Displaying results 481 - 490 of 4233 in total
  1. Drug

    Pancuronium

    go.drugbank.com/drugs/DB01337
    Approved

    As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.

  2. Drug

    Segesterone acetate

    go.drugbank.com/drugs/DB14583
    Approved

    As with other hormonal contraceptives, Annovera™ carries the risk for serious cardiovascular events. … Annovera™ is administered as a vaginal ring that is in place for 21 days and removed for 7 days each cycle.

  3. Drug

    Irbesartan

    go.drugbank.com/drugs/DB01029
    ApprovedInvestigational

    [L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy.

    Mixtures: IRBESARTAN HCT AUR 300/25, IRBESARTAN HCT AUR 300/25
  4. Drug

    Dipivefrin

    go.drugbank.com/drugs/DB00449
    ApprovedWithdrawn

    It is available as ophthalmic solution (eye drops).

  5. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    [A255582] Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. … It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).

  6. Drug

    Cetylpyridinium

    go.drugbank.com/drugs/DB11073
    ApprovedInvestigational

    Its salt form, cetylpyridinium chloride, is typically found as an active ingredient in mouthwashes, toothpastes, lozenges, throat sprays, breath sprays, and nasal sprays.

  7. Drug

    Lenograstim

    go.drugbank.com/drugs/DB13144
    ApprovedWithdrawn

    Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.

  8. Drug

    Tagraxofusp

    go.drugbank.com/drugs/DB14731
    ApprovedInvestigational

    [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is

  9. Drug

    Tetradecyl hydrogen sulfate (ester)

    go.drugbank.com/drugs/DB11328
    Approved

    Sodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids

  10. Drug

    Defibrotide

    go.drugbank.com/drugs/DB04932
    ApprovedInvestigational

    In the USA it is was approved in March, 2016 as Defitelio.